Vedolizumab for the treatment of Crohn’s disease

References

• Baumgart DC, Sandborn WJ. Crohn’s disease. The Lancet. 2012 Nov 3;380(9853):1590–1605. doi: 10.1016/S0140-6736(12)60026-9. Epub: 2012 Aug 20.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641–1657.
   PubMed Web of Science ®Google Scholar
• Sands BE. Inflammatory bowel disease: past, present, and future. Journal of Gastroenterology. 2007;42:16–25.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627–1640.
   PubMed Web of Science ®Google Scholar
• Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307–317.
   PubMed Web of Science ®Google Scholar
• Colombel J-F, Narula N, Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology [Internet]. 2017;152:351–361.
   PubMed Web of Science ®Google Scholar
• Kim DH, Cheon JH. Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies. Immune Netw. 2017;17(1):25.
   PubMed Web of Science ®Google Scholar
• Bossuyt P, Vermeire S. Treat to target in inflammatory bowel disease. Curr Treat Options Gastroenterol. 2016;14(1):61–72.
   PubMedGoogle Scholar
• Furfaro F, Gilardi D, Allocca M, et al. IL-23 blockade for Crohn s disease: next generation of anti-cytokine therapy. Expert Rev Clin Immunol. 2017 May;13(5):457–467.
   PubMed Web of Science ®Google Scholar
• Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. Journal of Crohn’s and Colitis. 2010; 4: 355–366.
   Google Scholar
• Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Alimentary Pharmacology and Therapeutics. 2011;33:987–995.
   PubMed Web of Science ®Google Scholar
• Roda G, Jharap B, Neeraj N, et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7(1):e135.
   PubMed Web of Science ®Google Scholar
• Wheat CL, Ko CW, Clark-Snustad K, et al. Inflammatory bowel disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis. BMC Gastroenterol. 2017;1–15.
   Google Scholar
• Haens GD, Reinisch W, Colombel J, et al. Five-year safety data from ENCORE, a European observational safety registry for adults with Crohn’s disease treated with infliximab [Remicade ®] or conventional therapy. Journal of Crohn's and Colitis. 2017;11(6):680–689.
   Google Scholar
• Biancone L, Annese V, Ardizzone S, et al. Safety of treatments for inflammatory bowel disease : clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Dig Liver Dis. 2017;49:338–358.
   Google Scholar
• Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology. 2004 May;126(6):1593–1610.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Vermeire S, Rutgeerts P. Optimizing treatment of inflammatory bowel diseases with biologic agents. Curr Gastroenterol Rep. 2008 Dec;10(6):591–596.
   PubMedGoogle Scholar
• Lorenzetti R, Zullo A, Ridola L, et al. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. Ann Med [Internet]. 2014;46(7):547–554.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016;14(10):1385–1397.e10.
   PubMed Web of Science ®Google Scholar
• Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut [Internet]. 2012;61(6):918–932.
   PubMed Web of Science ®Google Scholar
• Fiorino G, Correale C, Fries W, et al. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease. Expert Rev Clin Immunol. 2010;6(4):567–572.
   PubMed Web of Science ®Google Scholar
• Cesarini M, Fiorino G. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease-an update. Expert Rev Clin Immunol. 2013;9(4):301–306.
   PubMed Web of Science ®Google Scholar
• Furfaro F, Fiorino G, Allocca M, et al. Emerging therapeutic targets and strategies in Crohn’s disease. Expert Rev Gastroenterol Hepatol. 2016;10(6):735–744.
   PubMed Web of Science ®Google Scholar
• Chan HCH, Ng SC. Emerging biologics in inflammatory bowel disease. Journal of Gastroenterology. 2017;52:141–150.
   PubMed Web of Science ®Google Scholar
• Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006;12:S3–9.
   PubMed Web of Science ®Google Scholar
• Dart RJ, Samaan MA, Powell N, et al. Vedolizumab : toward a personalized therapy paradigm for people with ulcerative colitis. Clinical and experimental Gastroenterology. 2017;10:57–66.
   Google Scholar
• Stefanelli T, Malesci A, De La Rue SA, et al. Anti-adhesion molecule therapies in inflammatory bowel disease: touch and go. Autoimmun Rev. 2008 May;7(5):364–369.
   PubMed Web of Science ®Google Scholar
• Argollo M, Fiorino G, Hindryck P, et al. Novel therapeutic targets for inflammatory bowel disease. J Autoimmun. 2017 Dec;85:103–116.
   PubMed Web of Science ®Google Scholar
• Danese S, Panes J. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology. 2014;147(5):981–989.
   PubMed Web of Science ®Google Scholar
• Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn’s disease. Gastroenterology. 2001 Aug;121(2):268–274.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn’s disease. N Engl J Med. 2003 Jan;348(1):24–32.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005 Nov;353(18):1912–1925.
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE trial. Gastroenterology. 2007;132(5):1672–1683.
   PubMed Web of Science ®Google Scholar
• Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870–1880.
   PubMed Web of Science ®Google Scholar
• Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohn’s Colitis [Internet]. 2016;10(12):1437–1444.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–721.
   PubMed Web of Science ®Google Scholar
• Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab inductio. Gastroenterology. 2014;147(3):618–627.e3.
   PubMed Web of Science ®Google Scholar
• Sands BE, Sandborn WJ, Van Assche G, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease in patients naïve to or who have failed tumor necrosis factor antagonist therapy. Inflamm Bowel Dis. 2017;23(1):97–106.
   Google Scholar
• Ordas I, Mould DR, Feagan BG, et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012 Apr;91(4):635–646.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Vermeire S, Vogelsang H, et al. Effect of PF-00547659 on central nervous system immune surveillance and circulating beta7+ T cells in Crohn’s disease: report of the TOSCA study: MADCAM-1Antibody and CNS immune surveillance. J Crohns Colitis. 2017 Jan 24;12(2):188–196.
   Web of Science ®Google Scholar
• Colombel J-F, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017;66(5):839–851.
   PubMed Web of Science ®Google Scholar
• Wyant T, Leach T, Sankoh S, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut. 2015;64(1):77–83.
   PubMed Web of Science ®Google Scholar
• Rosario M, Dirks NL, Gastonguay MR, et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s disease. Aliment Pharmacol Ther. 2015;42(2):188–202.
   PubMed Web of Science ®Google Scholar
• Soler D, Chapman T, Yang -L-L, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330(3):864–875.
   PubMed Web of Science ®Google Scholar
• Rosario M, Wyant T, Leach T, et al. Vedolizumab pharmacokinetics, pharmacodynamics, safety, and tolerability following administration of a single, ascending, intravenous dose to healthy volunteers. 2016.
   Google Scholar
• Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn’s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 2008 Dec;6(12):1370–1377.
   PubMed Web of Science ®Google Scholar
• Rosario M, French JL, Dirks NL, et al. Exposure–efficacy relationships for vedolizumab induction therapy in patients with ulcerative colitis or Crohn’s disease. J Crohn’s Colitis. 2017;11(8):921–929.
   Google Scholar
• Williet N, Boschetti G, Fovet M, et al. Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseaseswith need for additional doses within 6 months. Clin Gastroenterol Hepatol. 2016 Nov;15(11):1750–1757.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Loftus EVJ, Colombel J-F, et al. Long-term efficacy of vedolizumab for Crohn’s disease. J Crohns Colitis. 2017 Apr;11(4):412–424.
   PubMed Web of Science ®Google Scholar
• Amiot A, Roblin X, Pariente MSLPJFB, et al. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017;46:310–321.
   Google Scholar
• Kopylov U, Ron Y, Avni-Biron I, et al. Efficacy and safety of vedolizumab for induction of remission in inflammatory bowel disease-the Israeli real-world experience. Inflamm Bowel Dis. 2017 Mar;23(3):404–408.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Singh S, Jiang X, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: results from the US VICTORY consortium. Am J Gastroenterol. 2016 Aug;111(8):1147–1155.
   PubMed Web of Science ®Google Scholar
• Amiot A, Grimaud J, Peyrin-Biroulet L, et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016 Nov;14(11):1593–1601.
   Google Scholar
• Engel T, Ungar B, Yung DE, et al. Vedolizumab in IBD – lessons from real-world experience; a systematic review and pooled analysis. J Crohn’s Colitis. 2018 Jan 24;12(2):245–257.
   Google Scholar
• Bye WA, Jairath V, Travis SPL. Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2017 Jul;46(1):3–15.
   Web of Science ®Google Scholar
• Vermeire S. Long-term efficacy of vedolizumab for Crohn’s disease. 2016.
   Google Scholar
• Bian S, Dreesen E, Tang HT, et al. Antibodies toward vedolizumab appear from the first infusion onward and disappear over time. Inflamm Bowel Dis. 2017 Dec;23(12):2202–2208.
   PubMed Web of Science ®Google Scholar
• Kurti Z, Vegh Z, Golovics PA, et al. “Treat to Target” - lessons learnt. Dig Dis. 2016;34(1–2):147–152.
   PubMed Web of Science ®Google Scholar
• Shah SC, Colombel JF, Sands BE, et al. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn’s disease. Aliment Pharmacol Ther. 2016;43(3):317–333.
   PubMed Web of Science ®Google Scholar
• Noman M, Ferrante M, Bisschops R, et al. Vedolizumab induces long term mucosal healing in patients with Crohn’s disease and ulcerative colitis. J Crohns Colitis. 2017 Sep 1;11(9):1085–1089.
   PubMedGoogle Scholar
• Vavricka SR, Schoepfer A, Scharl M, et al. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(8):1982–1992.
   Google Scholar
• Vavricka SR, Scharl M, Gubler M, et al. Biologics for extraintestinal manifestations of IBD. Curr Drug Targets. 2014;15(11):1064–1073.
   PubMed Web of Science ®Google Scholar
• Wendt E. CCR9 antagonism: potential in the treatment of inflammatory bowel disease. Clinical and experimental Gastroenterology. 2015;8:119–130.
   Google Scholar
• Halilbasic E, Fuchs C, Hofer H, et al. Therapy of primary sclerosing cholangitis–today and tomorrow. Dig Dis. 2015;33(Suppl 2):149–163.
   PubMedGoogle Scholar
• Stine JG, Wang J, Behm BW. Chronic cholestatic liver injury attributable to vedolizumab. J Clin Transl Hepatol. 2016;4(3):277–280.
   PubMedGoogle Scholar
• Mahadevan U, Vermeire S, Lasch K, et al. Alimentary pharmacology and therapeutics vedolizumab exposure in pregnancy: outcomes from clinical studies in in fl ammatory bowel disease. Aliment Pharmacol Ther. 2017 Apr;45(7):941–950.
   Google Scholar
• Beaulieu DB, Kane S. Inflammatory bowel disease in pregnancy. World J Gastroenterol. 2011 Jun;17(22):2696–2701.
   PubMed Web of Science ®Google Scholar
• Huang VW, Habal FM. From conception to delivery: managing the pregnant inflammatory bowel disease patient. World J Gastroenterol. 2014;20(13):3495–3506.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Mahadevan U. Pregnancy concerns in women with inflammatory bowel disease. Gastroenterol Hepatol. 2015;11(4):273–275.
   Google Scholar
• Mahadevan U, Vermeire S, Lasch K, et al. Editorial: vedolizumab in pregnancy ??? is gut selectivity as good for baby as it is for mum? Authors??? reply. Aliment Pharmacol Ther. 2017;45(9):1284.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Vermeire S, Lasch K, et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther. 2017 Apr;45(7):941–950.
   PubMed Web of Science ®Google Scholar
• Conrad MA, Stein RE, Maxwell EC, et al. Vedolizumab therapy in severe pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(10):2425–2431.
   PubMed Web of Science ®Google Scholar
• Singh N, Rabizadeh S, Jossen J, et al. Multi-center experience of vedolizumab effectiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(9):2121–2126.
   PubMed Web of Science ®Google Scholar
• Ledder O, Assa A, Levine A, et al. Vedolizumab in paediatric inflammatory bowel disease: a retrospective multi-centre experience from the paediatric IBD porto group of ESPGHAN. J Crohn’s Colitis. 2017;11(10):1230–1237.
   Google Scholar
• Fuchs F, Schillinger D, Atreya R, et al. Clinical response to vedolizumab in ulcerative colitis patients is associated with changes in integrin expression profiles. Front Immunol. 2017 Jul 3;8:764.
   Google Scholar